Your browser doesn't support javascript.
loading
Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale.
Hallqvist, Andreas; Svensson, Johanna; Hagmarker, Linn; Marin, Ida; Rydén, Tobias; Beauregard, Jean-Mathieu; Bernhardt, Peter.
Afiliação
  • Hallqvist A; Department of Oncology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 41345 Gothenburg, Sweden.
  • Svensson J; Department of Oncology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 41345 Gothenburg, Sweden.
  • Hagmarker L; Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, 43415 Gothenburg, Sweden.
  • Marin I; Department of Medical Radiation Sciences, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 43415 Gothenburg, Sweden.
  • Rydén T; Department of Medical Radiation Sciences, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 43415 Gothenburg, Sweden.
  • Beauregard JM; Department of Medical Imaging, CHU de Québec-Université Laval, Quebec City, QC G1R 3S1, Canada.
  • Bernhardt P; Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC G1R 3S1, Canada.
Biomedicines ; 9(11)2021 Oct 29.
Article em En | MEDLINE | ID: mdl-34829796
ABSTRACT
177Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells to repair 177Lu-induced DNA damage. To decrease the risk of side effects, the sequencing should be optimized according to the tumour-to-normal tissue enhanced dose ratio (TNED). The aim of this study was to investigate how to enhance 177Lu-DOTATATE by optimal timing of the addition of a PARP inhibitor. Biokinetic modelling was performed based on the absorbed dose to the bone marrow, kidneys and tumour; determined from SPECT/CT and planar images from 17 patients treated with 177Lu-DOTATATE. To investigate the theoretical enhanced biological effect of a PARP inhibitor during 177Lu-DOTATATE treatment, the concept of relative biological effectiveness (RBE) was used, and PARP inhibitor administration was simulated over different time intervals. The absorbed dose rate for the tumour tissue demonstrated an initial increase phase until 12 h after infusion followed by a slow decrease. In contrast, the bone marrow showed a rapid initial dose rate decrease. Twenty-eight days after infusion of 177Lu-DOTATATE, the full absorbed dose to the bone marrow and kidney was reached. Using an RBE value of 2 for both the tumour and normal tissues, the TNED was increased compared to 177Lu-DOTATATE alone. According to the modelling, the PARP inhibitor should be introduced approximately 24 h after the start of 177Lu-DOTATATE treatment and be continued for up to four weeks to optimize the TNED. Based on these results, a phase I trial assessing the combination of olaparib and 177Lu-DOTATATE in somatostatin receptor-positive tumours was launched in 2020 (NCT04375267).
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2021 Tipo de documento: Article